Drugs / JTT-851
last change Jul 2013 re-read 2 minutes ago

JTT-851

Developed for
type 2 diabetes mellitus
Investigated by
Akros Pharma Inc.

Trials 1 · a red edge is where a trial was stopped

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01699737 Sep 2012 → May 2013 type 2 diabetes mellitus Akros Pharma Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as JTT-851 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01699737
Route Oral “JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks” NCT01699737